Search

everythinglearnresearchcommunity

for

Search:↓

Some users believe creatine may accelerate hair loss, while others see no effect. Opinions are mixed, with some suggesting using treatments like finasteride to counter potential effects.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

A 19-year-old diagnosed with AGA was refused finasteride by a dermatologist who cited fertility concerns and prescribed minoxidil, vitamins, and shampoos instead. The user is unsure about using minoxidil and considers finding another dermatologist.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.

An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.

Caffeine liquid may be as effective as Minoxidil for hair loss and could be used together for added benefits. However, the credibility of the research is questionable due to potential bias, as the study was sponsored by a company that sells caffeine solution and was not double-blind.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The user is concerned about the safety of combining 4mg oral Minoxidil, 450mg caffeine, and 6 hours of intense weight lifting. They are seeking reassurance that this combination won't be harmful.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

The post discusses the use of El-Cranell, which contains Alfatradiol, and Quercetin as a treatment for hair loss. The user is seeking recommendations on the amount of Quercetin to add to the solution. The conclusion of the document is that Quercetin has been shown to stimulate hair growth and inhibit DHT, and combining it with zinc/copper may have a synergistic effect.

The conversation discusses the potential impact of creatine on hair loss, with some users sharing personal experiences of increased shedding while others argue there's no scientific evidence linking creatine to hair loss. The original poster switched from finasteride to dutasteride and is considering resuming creatine after monitoring its effects on hair loss.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

A user humorously suggested smoking minoxidil in a blunt as an alternative hair growth method, sparking a satirical discussion on unconventional and unsafe ways to use minoxidil. The conversation included various suggestions like oral pills, rectal administration, and other absurd methods, with some users warning against the dangers of such practices.

The user experiences side effects from minoxidil and is considering alternatives like stemoxydine and adenosine for hair regrowth and density, but finds options like caffeine and various oils unreliable. They are also using a 5AR inhibitor (finasteride).

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

Long-term use of dutasteride may impair semen volume and sperm motility, but these effects are often reversible after stopping the drug. Individual reactions vary, and more research is needed to understand the long-term impact on fertility.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.